skip to main content

Eisenmenger Syndrome — EECC MCQ

Instant feedback + full explanation. One question, done properly.

EasyCongenital Heart Disease (Adult)Eisenmenger SyndromeEECC

A 30-year-old woman with Eisenmenger syndrome secondary to a large VSD is reviewed. Her resting oxygen saturations are 82% on room air. She reports worsening exercise tolerance. Which class of pulmonary vasodilator has the strongest evidence for improving exercise capacity in Eisenmenger syndrome?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: AEndothelin receptor antagonists (e.g. bosentan)

Explanation lettering: B = shown as A · D = shown as B · A = shown as D

Per the 2020 ESC ACHD Guidelines and 2022 ESC PH Guidelines, bosentan has the strongest evidence base in Eisenmenger syndrome from the BREATHE-5 trial showing improved 6MWD and reduced PVR. PDE5 inhibitors (A) are also used but evidence is less robust. CCBs (C) are not recommended in Eisenmenger. Prostacyclins (D) are used in severe PAH but less studied here. Riociguat (E) is not studied in Eisenmenger syndrome.

Reference: ESC (2022): Guidelines on Pulmonary Hypertension